RenovoRx Reports Promising Q1 2025 Financial Results

Renovorx, Inc. ( (RNXT) ) has released its Q1 earnings. Here is a breakdown of the information Renovorx, Inc. presented to its investors.

RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies, primarily through its FDA-cleared drug-delivery device, RenovoCath, which is part of its innovative Trans-Arterial Micro-Perfusion (TAMP) therapy platform. In the first quarter of 2025, RenovoRx reported its first full quarter of commercial sales for RenovoCath, generating approximately $200,000 in revenue, surpassing internal expectations. The company anticipates continued revenue growth as it expands its customer base and progresses with its Phase III TIGeR-PaC clinical trial. Key financial highlights include a cash position of $14.6 million, which is expected to support the commercialization scale-up and trial completion, as well as increased R&D and SG&A expenses compared to the previous year. Despite a net loss of $2.4 million, RenovoRx remains optimistic about its market potential, estimating a $400 million peak annual U.S. sales opportunity for RenovoCath. Looking forward, RenovoRx is focused on completing the TIGeR-PaC trial enrollment in 2025 and exploring further commercialization opportunities for its TAMP technology.